Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2002

View Archived Issues

Wyeth patents novel antiatherosclerotic agents

New analgesics in the Gruenenthal pipeline

Carbapenem antibiotics presented by Banyu

Toa Eiyo claims chymase inhibitors for use in hypertension and other disorders

Cell adhesion inhibitors and their use in asthma, inflammation, etc.

Nikken Chemicals patents TNF-alpha production inhibitors

Quinolines and isoquinolines identified as factor Xa inhibitors

Endostatin enters phase II trial in stage IV metastatic melanoma

Wilex and Aventis sponsor phase III trial in high-risk breast cancer

Preliminary data from human studies on gimatecan reported in Orlando

Opioid treatment of IBS associated with constipation provides symptom relief

ASCO presentation reports preliminary PK data and good tolerance for ILX-651

Dolastatin 10 assessed in phase II trial in advanced renal cell carcinoma at Mayo Clinic

Two different schedules of administration for AG-2037 under study in cancer patients

Preclinical and clinical results presented at major cancer meeting for SAHA, an HDAC inhibitor

Spotlight on topoisomerase inhibitors under development

AnorMED reviews fiscal 2002 and anticipates 2003 milestones

NP-1 enters phase II trials in neuropathic pain

Arena and Ferring collaborate on drug discovery in reproductive health

Novirio changes name to Idenix

NV-04 moves into clinical testing in cardiovascular disease

SIGA Technologies awarded SBIR grant for antibiotic development

IND filed for MDX-060

Genelabs expects Aslera NDA response by August 2002

Oncophage granted orphan drug status in renal cell carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...